3,842 reports of this reaction
3.6% of all MOMETASONE FUROATE reports
#3 most reported adverse reaction
DYSPNOEA is the #3 most commonly reported adverse reaction for MOMETASONE FUROATE, manufactured by L. Perrigo Company. There are 3,842 FDA adverse event reports linking MOMETASONE FUROATE to DYSPNOEA. This represents approximately 3.6% of all 107,848 adverse event reports for this drug.
MOMETASONE FUROATE has an overall safety score of 78 out of 100. Patients taking MOMETASONE FUROATE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among MOMETASONE FUROATE users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for MOMETASONE FUROATE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 3,842 FDA reports for MOMETASONE FUROATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.6% of all adverse event reports for MOMETASONE FUROATE, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking MOMETASONE FUROATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.